Views & Analysis Orphan drugs will fuel pharma's future - and a pricing pushb... Evaluate predicts sales could approach $8bn if approved.
News AZ sells US/Canada rights for old breast cancer drug AstraZeneca has sold US and Canadian rights to its older breast cancer drug Zoladex to TerSera Therapeutics in a deal worth up to $320 million.
Partner Content Partner Content Immuno-Oncology: A 360° View in NYC this February The Conference Forum has announced that the 3rd annual
News BMS and PsiOxus to collaborate on cancer-targeting armed vir... BMS to pay up to $936m for NG-348.
News AZ stakes its claim in immunotherapy with bladder cancer fil... After looking like it could get left far behind by rivals in immunotherapy, AstraZeneca has made its first filing for PD-L1 drug durvalumab .
News Avelumab filed, Pfizer and Merck prepare to join immunothera... Checkpoint inhibitor drug set to be fourth competitor in PD-1/PD-L1 market
News Relief for AZ as Truqap hits the spot in prostate cancer After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
